Page last updated: 2024-11-12

tirucallane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tirucallane: from Simarouba amara (Simaroubaceae); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tirucallane : A triterpene that is (13alpha,14beta,17alpha,20S)-lanostane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Simarouba amaraspecies[no description available]SimaroubaceaeA plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida. Leaves are alternate and compound. Most have small flowers, bitter bark, and fleshy fruits that are sometimes winged. Members contain QUASSINS.[MeSH]

Cross-References

ID SourceID
PubMed CID12312922
CHEBI ID73301
MeSH IDM0503396

Synonyms (13)

Synonym
tirucallane
CHEBI:73301
(13alpha,14beta,17alpha,20s)-lanostane
Q27140423
unii-cwp59nf9tf
lanostane, (13alpha,14beta,17alpha,20s)-
2151853-72-2
cwp59nf9tf ,
(5s,8r,9s,10r,13s,14r,17s)-4,4,10,13,14-pentamethyl-17-((2s)-6-methylheptan-2-yl)-2,3,5,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta(a)phenanthrene
DTXSID501310798
lanostane, (13.alpha.,14.beta.,17.alpha.,20s)-
(13.alpha.,14.beta.,17.alpha.,20s)-lanostane
(5s,8r,9s,10r,13s,14r,17s)-4,4,10,13,14-pentamethyl-17-[(2s)-6-methylheptan-2-yl]-2,3,5,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpeneA C30 terpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (7.14)29.6817
2010's42 (75.00)24.3611
2020's10 (17.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.61 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]